Scenic Biotech BV announces $31m financing
Scenic Biotech BV will use an incoming $31m (28) Series A financing to advance its pipeline of genetic modifiers, a new molecular entity in cancer and rare disease.
·
Kurma Partners closes growth fund at 160m
French venture capital expert Kurma Partners has closed its Growth Opportunities Fund at 160m and targets a final closing at 250m.
mRNA for Africa
Moderna will build its first mRNA production facility in Kenya, investing up to US$500m.
Epsilogen raise £30.75m in Series B financing
IgE cancer antibody specialist Epsilogen Ltd has closed a £30.75m round led by Novartis Venture Fund to advance Phase Ib studies with MOv18 IgE in platinum-resistant ovarian cancer.
Syndesi swallowed by Abbvie
AbbVie has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie’s neuroscience portfolio.
Meletios Therapeutics licences antiviral patent
Paris-based Meletios Therapeutics SA has licenced know-how from the Institut Pasteur for the development of a new class of antivirals-
TargED Biopharmaceuticals BV raises 39m in Series A financing
TargED Biopharmaceuticals will use 39m from a Series A financing to bring its thrombolytic treatment to patients.
Finnish VTT spin-out Onego Bio Ltd raises 10m
The cellular agriculture spin-off Onego Bio Ltd has been seeded with 10m to use its Trichoderma platform to establish an animal-free egg protein production.
Moderna wants to extent its European footprint
The former mRNA start-up Moderna Inc is set to expand its commercial network in six European nations to become a gobally active vaccine company.
Centauri Therapeutics starting with £24m financing
Antimicrobial resistance specialist Centauri Therapeutics Ltd has closed a £24m Series A round to identify novel therapeutic candidates using the Alphamer technology.